Resources for You
Levaquin (Levofloxacin) Tablets, Oral Solution and Injection
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2012
WARNINGS AND PRECAUTIONS
Musculoskeletal Disorders in Pediatric Patients and Arthropathic Effects in Aninmals
- Levaquin is indicated in pediatric patients (6 months of age and older) only for the prevention of inhalational anthrax (post-exposure) and for plague. An increased incidence of musculoskeletal disorders (arthralgia, arthritis, tendinopathy, and gait abnormality) compared to controls has been observed in pediatric patients receiving Levaquin.